uniQure (NASDAQ: QURE) will release its second quarter 2026 financial results before the U.S. market opens on Wednesday, July 29, 2026. Management will host an earnings conference call the same day at 8:30 a.m. ET, with a live webcast available in the Events & Presentations section of the company’s website.
A replay of the webcast will be archived for 90 days. Analysts can join the Q&A session by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID 5075555, and are advised to connect 15 minutes before the start time.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – QURE
+0.72%
+0.72%Session close to close
In the Jul 22 session, QURE gained 0.72%, reflecting a mild positive market reaction.
The prior earnings-date record included a 0.84% 24-hour move, adding historical context to this sche...
Analysis
The prior earnings-date record included a 0.84% 24-hour move, adding historical context to this scheduling notice. Recent insider activity was classified as Net Selling; the July 29 results are the next factual checkpoint.
"uniQure, a leading gene therapy company advancing transformative therapies"
Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.
genomic medicinemedical
"a major milestone in the field of genomic medicine"
Genomic medicine uses a person’s DNA blueprint to diagnose disease, choose treatments, and develop drugs that target specific genetic features. For investors, it matters because therapies and tests based on genetic information can change who benefits from a drug, shorten development timelines, and create high-value niche products or diagnostic markets—like replacing a one-size-fits-all map with a customized GPS for treatment decisions.
hemophilia Bmedical
"uniQure’s gene therapy for hemophilia B"
A genetic bleeding disorder caused by a shortage of a blood protein needed to form clots, so small injuries can cause prolonged bleeding; think of it like a pipe that won’t seal properly after a leak. It matters to investors because treatments — from regular replacement therapies to one-time gene therapies — drive long-term revenue, regulatory risk and large R&D and market opportunities in healthcare companies focused on blood disorders.
A form of epilepsy where seizures start in the brain’s temporal lobe and continue despite treatment with multiple appropriate anti-seizure medications; think of it as a stubborn electrical short in a specific part of the brain that standard fixes don’t stop. It matters to investors because it defines a patient group with persistent unmet medical needs, driving demand for new drugs, devices, clinical trials, specialist care and potential healthcare spending.
~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~
LEXINGTON, Mass. and AMSTERDAM, July 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2026 financial results before market open on Wednesday, July 29, 2026. Management will then host a conference call at 8:30 a.m. ET.
The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID 5075555. If you are joining the conference call, please join 15 minutes before the start time.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com
When will uniQure (NASDAQ: QURE) report its Q2 2026 financial results?
uniQure plans to report its second quarter 2026 financial results on Wednesday, July 29, 2026, before the U.S. market opens. According to uniQure, the release will be followed by a management conference call that morning.
What time is the uniQure (QURE) Q2 2026 earnings conference call on July 29, 2026?
The uniQure second quarter 2026 earnings conference call is scheduled for 8:30 a.m. ET on July 29, 2026. According to uniQure, participants should join about 15 minutes early to ensure timely access.
How can investors access the uniQure (QURE) Q2 2026 earnings webcast and replay?
Investors can access the live webcast under the Events & Presentations section of uniQure’s website. According to uniQure, a replay of the event will be archived on the site for approximately 90 days after the call.
What are the dial-in details for analysts joining the uniQure (QURE) Q2 2026 earnings call?
Analysts can join the uniQure Q2 2026 call by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID 5075555. According to uniQure, these numbers allow participation in the question-and-answer session.
What therapeutic areas is uniQure (QURE) focused on as of July 2026?
uniQure focuses on gene therapies for severe diseases, including hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, and Fabry disease. According to uniQure, its approved hemophilia B therapy reflects over a decade of research and clinical development.
